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A B S T R A C T
The ability to selectively eradicate oncogene-addicted tumors while reducing systemic toxicity has endeared
targeted therapies as a treatment strategy. Nevertheless, development of acquired resistance limits the benefits
and durability of such a regime. Here we report evidence of enhanced reliance on mitochondrial oxidative
phosphorylation (OXPHOS) in oncogene-addicted cancers manifesting acquired resistance to targeted therapies.
To that effect, we describe a novel OXPHOS targeting activity of the small molecule compound, OPB-51602
(OPB). Of note, a priori treatment with OPB restored sensitivity to targeted therapies. Furthermore, cancer cells
exhibiting stemness markers also showed selective reliance on OXPHOS and enhanced sensitivity to OPB.
Importantly, in a subset of patients who developed secondary resistance to EGFR tyrosine kinase inhibitor (TKI),
OPB treatment resulted in decrease in metabolic activity and reduction in tumor size. Collectively, we show here
a switch to mitochondrial OXPHOS as a key driver of targeted drug resistance in oncogene-addicted cancers. This
metabolic vulnerability is exploited by a novel OXPHOS inhibitor, which also shows promise in the clinical
setting.
1. Introduction
The process of carcinogenesis and its progression is a functional
outcome of dysregulation of several critical regulatory networks/
pathways that maintain tissue and organ homeostasis. Thanks to the
tremendous strides in the development of novel technologies and
platforms, there has been an enormous advancement in our under-
standing of the processes involved in the various stages of cellular
transformation, in particular, the tight balance between proteins pro-
ducts of genes that promote carcinogenesis and those that serve to
suppress neoplastic transformation [1]. Notably, recent observations
provide support to the hypothesis that a transformed cell might call on
different sources of energy to keep up with the high anabolic needs
from the point of initiation to expansion and progression of carcino-
genesis [2–4]. In this regard, the preferred reliance on glucose as the
essential source of carbon in cancer cells formed the basis for the
Warburg effect. The relative increase in the shuttling of glucose-derived
pyruvate to lactate during this switch is a function of induced expres-
sion of lactate dehydrogenase (LDH) even in the presence of oxygen
and/or increased expression of pyruvate kinase M2 isoform (PK-M2)
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[5], which is not the only transcriptional target of hypoxia inducible
factor-1α (Hif-1α) [5,6]. While the Warburg effect is a well-established
phenomenon associated with the process of carcinogenesis, there is also
evidence linking the activation of oncogenes, such as Ras andMyc, to an
increase in mitochondrial OXPHOS [3]. Furthermore, there is also ex-
perimental evidence that mitochondrial metabolism is not entirely shut
down but might exhibit significantly low to even appreciably high ac-
tivity in cancer cells. This data suggests the possibility that different cell
states during the process of carcinogenesis utilize disparate fuel sources
to keep up with the increased metabolic demands. The latter is corro-
borated by a recent study by Yu et al., which postulates the existence of
a “hybrid state”, in which both metabolic modes coexist [7].
As a matter of fact, metabolic adaptions [8] have been reported to
play a role in not only conferring resistance to targeted therapies in
oncogene-addicted cancer cells, but also in the refractory behavior of
cancer stem cells (CSCs). It is tempting to hypothesize that the activa-
tion of surrogate/compensatory survival networks, such as STAT3 [9],
MET [10,11], and PI3K/Akt [12], as a mechanism of resistance to
targeted therapies in oncogene-addicted cancer cells could be asso-
ciated with metabolic reprogramming to a predominantly OXPHOS-
driven milieu. Indeed, using several models of oncogene-addicted
cancers with acquired resistance to oncogene-targeted therapy, such as
TKI, we present evidence indicating reprogramming to a predominantly
OXPHOS-dependent metabolism. Of note, in a search to identify small
molecules with selectivity towards OXPHOS-driven cancers, we unravel
a novel biological activity of a small molecule compound, OPB (Otsuka
Pharmaceuticals) [13,14]. Oncogene-addicted cancers with acquired
resistance to targeted therapy exhibit enhanced sensitivity to OPB via
mechanisms that involve inhibition of mitochondrial oxygen con-
sumption and complex I activity. More importantly, the clinical vali-
dation of the anti-tumor activity strongly suggests a novel therapeutic
strategy for refractory cancers. Taken together, this data demonstrates
that oncogene-addicted cancers reprogram their metabolism to pre-
dominantly OXPHOS-driven and highlight the tremendous therapeutic
potential of exploiting this acquired vulnerability.
2. Results
2.1. Oncogene-addicted cancer cells with acquired resistance to targeted
therapy exhibit elevated aerobic mitochondrial respiration
We first established cell line models of acquired resistance to tar-
geted therapies, to identify common resistance mechanisms. HCC827 is
an EGFR-mutant NSCLC cell line that is sensitive to the EGFR small
molecule inhibitor, gefitinib, while A375 is a BRAF-mutant melanoma
cell line that is sensitive to the BRAF small molecule inhibitor, ve-
murafenib. The respective cell lines were cultured with increasing
concentrations of gefitinib or vemurafenib to obtain the gefitinib-re-
sistant HCC827 cells (HCC827-GR) and the vemurafenib-resistant A375
cells (A375-VR) (Supp. Fig. 1A). NSCLC cell line H1975 has a T790M
EGFR mutation, thus conferring inherent resistance to EGFR inhibitors.
Given that up-regulated STAT3 signaling was reported as a compensa-
tory resistance mechanism to targeted therapies [9], we explored this
phenomenon in our model cell lines. Indeed, HCC827-GR and A375-VR
cell lines displayed increased STAT3 phosphorylation at Tyrosine 705
(p-Tyr705) but not at serine 727 (p-S727) (Supp. Fig. 1B) and elevated
levels of interleukin-6 [IL-6] (Supp. Fig. 1C). Notably, the therapy-re-
sistant cell lines, HCC827-GR and A375-VR, elicited significant ampli-
fication in mitochondrial oxygen consumption [OCR] (Fig. 1A) com-
pared to their parental counterparts, which is indicative of increased
mitochondrial OXPHOS activity. To further corroborate the link be-
tween therapy resistance in oncogene-addicted cells and increased
mitochondrial OXPHOS, we expanded our investigations to three other
model systems, i.e., crizotinib-resistant H2228 cells (H2228-CR), T315I
mutant BaF3 cells (BaF3T315I) and MDA-MB-231 triple negative breast
cancer (TNBC) cells. Interestingly, increased basal OCR was con-
sistently observed in H2228-CR and BaF3T315I cells (Fig. 1A) as well as
in MDA-MB-231 cells (Supp. Fig. 1D), compared to their respective
control cell lines. Furthermore, the switch to OXPHOS in the resistant
cell lines could possibly be accounted for by the amplification in mi-
tochondrial-DNA content [mtDNA] (Fig. 1B), increase in mitochondrial
mass as evidenced by upregulation of PGC1α and TFAM expression
(Fig. 1C) and appearance of complex I and II supercomplexes formation
upon Blue-Native polyacrylamide gel electrophoresis (BN-PAGE) ana-
lyses of individual ETC (electron transport chain) complexes (Fig. 1D).
Taken together, these data provide testimony that therapy-resistant
oncogene-addicted cancers undergo reprogramming to an OXPHOS-
driven metabolism.
2.2. Small molecule compound OPB is a novel OXPHOS inhibitor
Intrigued by the significant increases in STAT3 phosphorylation and
mitochondrial OCR in oncogene-addicted therapy-resistant cancer cells,
we set out to investigate if the increase in STAT3 phosphorylation as-
sociated with oncogene-addicted TKI resistance was also the effector
mechanism triggering the metabolic switch to OXPHOS and more so if
this cell state afforded enhanced sensitivity to pharmacological in-
hibitors of STAT3 and/or OXPHOS. To verify these possibilities we
made use of two known pharmacological inhibitors of STAT3, Stattic
[15] and OPB [14], and two OXPHOS inhibitors, elesclomol [16] and
metformin [17]. Elesclomol was also identified in a high throughput
screen comprising of Selleckchem® compound libraries (anti-cancer and
epigenetics compound library) to selectively target HCC827-GR and
A375-VR cells (Supp. Fig. 1E, Fig. 1E). Notably, OPB elicited much
stronger inhibitory effects on mitochondrial respiration (Fig. 1F) and
cell survival (Fig. 1G) in HCC827 and HCC827-GR cells than the other
three compounds. In particular, the inhibitory effect of OPB on mi-
tochondrial respiration was even superior to the commonly used mi-
tochondrial complex I inhibitor, metformin (Fig. 1F). This is in agree-
ment with a recent finding highlighting OPB induced mitochondrial
dysfunction; however, the underlying mechanism described in that re-
port implicated the SH2 domain of STAT3 [14]. To gain further insight
into the OXPHOS inhibitory activity of OPB and its relationship to
STAT3 signaling, we first confirmed using KINOMEscan™ scanMAX that
OPB did not elicit significant off-target effects on a wide range of up-
stream kinases (Supp. Fig. 1F). Furthermore, similar to the results
shown with HCC827-GR, OPB elicited significantly better survival in-
hibitory activity against A375-VR cells and BaF3T315I cells compared
to the respective parental cell lines (Fig. 1H) as well as H1975 cells at
relatively low (nanomolar) IC50 concentrations (Supp. Fig. 1G). The
efficacy of OPB (in nanomolar range) was also validated in non-onco-
gene-addicted nasopharyngeal carcinoma cell lines HK-1 and C666-1
(Supp. Fig. 1H). This correlated with an inhibition of STAT3 phos-
phorylation at Y705 site (p-Tyr705) and IL-6 levels following OPB
treatment (Supp. Fig. 1I) as well as inhibition of dimerization of STAT3
(Supp. Fig. 1J), which was previously reported as the mechanism of
action of OPB. However, it is important to note that knockdown of
STAT3 failed to rescue cells from the growth inhibitory and OCR sup-
pressing effects of OPB (Supp. Fig. 2A-C), thus corroborating the
STAT3-independent mechanism of OXPHOS inhibition. Also, similar to
the oncogene-addicted cell lines, STAT3 knockdown did not rescue HK-
1 cells from the inhibitory effects of OPB (Supp. Fig. 2D). Finally, OPB
elicited striking in vivo potency in prolonging survival and reducing
tumor burden in murine xenograft models (Fig. 1I, Supp. Fig. 3). These
data lend credence to the possibility that the metabolic switch to OX-
PHOS is not only an independent mechanism of acquired-resistance but
may also represent a vulnerability that is efficiently targeted by the
small molecule compound, OPB.
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2.3. Drug-resistant oncogene-addicted cells are metabolically reprogrammed
to depend on OXPHOS for survival, representing a metabolic vulnerability to
OXPHOS inhibition
Fluxes in OCR upon sequential addition of specific mitochondrial
inhibitors and uncouplers are frequently used to indicate mitochondrial
(dys)function [18]. Firstly, the effect of OPB on basal OCR was assessed.
As shown in the earlier data, OPB treatment resulted in a significant
drop in the basal OCR of the oncogene-addicted TKI-resistant cells
(HCC827-GR, A375-VR and T315I, H396R and M315T mutation of
Baf3) and their respective parental cells (Fig. 2A). Next, the maximum
OCR upon dissipating the membrane potential with FCCP was assessed.
Interestingly, OPB treatment also resulted in a significant decrease in
maximum OCR (Fig. 2B), which was associated with a marked increase
in Extracellular Acidification Rate (ECAR) in the various cell line
models (Fig. 2C); increase in ECAR has been reported as a surrogate and
suggestive indicator of mitochondrial respiration inhibition [19]. The
latter was further corroborated by the significant increase in extra-
cellular lactate levels in OPB-treated H1975 cells (Fig. 2D). Further-
more, the effect of OPB on OCR was also assessed in the presence of
oligomycin (Oligo), FCCP, rotenone and antimycin A (Rot/AA), in-
hibitors of ETC complexes. Results indicate that exposure of H1975,
HK-1 and C-666-1 cells for 1 h to OPB completely suppressed mi-
tochondrial respiration with a reciprocal increase in ECAR (Fig. 2E-H).
Lastly, as mitochondrial OXPHOS is dependent on the supply of oxygen
for ATP generation, we evaluated the effect of hypoxia (4% O2 as
compared to 21% O2) on OPB-induced inhibition of ATP production.
Notably, while hypoxia was observed to reduce constitutive ATP levels,
OPB-induced cessation of ATP generation/levels was abrogated under
hypoxic states (Fig. 2I), thereby indicating the obligatory requirement
of active OXPHOS machinery in the mitochondria targeting activity of
OPB.
2.4. OPB mediates its effect on mitochondrial respiration through the
specific inhibition of mitochondrial Complex I activity
So far, results provided evidence to link the anti-cancer activity of
OPB to its inhibitory effect on mitochondrial OCR. Therefore, to further
elucidate the exact mechanism involved in the specific targeting of
oncogene-addicted cells that switch to OXPHOS for survival against
drug-induced execution was assessed. To that end, analysis of the ex-
pression profile of OXPHOS-regulating genes showed a dose dependent
downregulation of NDUFA9, NRF1, TFAM, PGC1α, and SOD2 in re-
sponse to OPB (Fig. 3A). Coupled to that, analysis of mitochondrial ETC
complexes by 2D SDS-PAGE following separation by BN-PAGE revealed
a significant decrease in Complex I subunit, NDUFA9 (circled) as well as
Complex II, IV and V (ATP Vα) (Fig. 3B). In addition, a significant in-
crease in mitochondrial superoxide (O2.-) was observed in cells fol-
lowing exposure to OPB (Supp. Fig. 4A), which further corroborates
with the inhibitory effects of OPB on OXPHOS. Intrigued by these
findings, we next set out to evaluate the effect of OPB on the activity of
the five key complexes of the mitochondrial ETC. Using bovine heart
mitochondria (BHM) as the standard for basal mitochondrial complex
activity, the effect of increasing concentrations of OPB on each of the
complexes was investigated. Notably, OPB exhibited inhibitory effect
on complex I activity in BHM (Fig. 3C) as well as in H1975 cells
(Fig. 3D), which was comparable to rotenone (Rot), a known complex I
inhibitor. No significant effect was observed on the activities of the
other four complexes (Supp. Fig. 4B), thereby indicating specific tar-
geting of Complex I. The Complex I-specific effect of OPB was corro-
borated by the significant reduction in NAD+/NADH ratio (Fig. 3E), a
parameter commonly used as an indicator of Complex I activity (NADH
dehydrogenase), as well as, by the signification reduction in the in-gel
activity using BN-PAGE (Fig. 3F). The remarkable similarity between
the effects of OPB and the bona fide complex I inhibitor, Rot, were also
verified in the NPC cell line model. While OPB rapidly inhibited mi-
tochondrial OCR, similarly as Rot, the further addition of Rot to OPB-
treated cells displayed no further reduction in OCR (Fig. 3G). In addi-
tion, a priori treatment with OPB was sufficient to dose-dependently
reduce basal OCR, with doses as low as 30 nM completely inhibiting
mitochondrial OCR in the same NPC cells (Fig. 3H). These data provide
sufficient evidence that the OCR regulatory activity of OPB is linked to
its ability to strongly inhibit Complex I activity, which could in part be
linked to the repression of the sub-unit, NDUFA9.
2.5. Cancer stem cells rely on OXPHOS for survival in drug-resistant
oncogene-addicted cells and are sensitive to OPB inhibition
Stimulated by the novel OCR targeting activity of the small mole-
cule compound OPB, we next set out to assess if the reported depen-
dence of CSC on OXPHOS [20,21] could present as a vulnerability that
might be exploited by specific OXPHOS inhibitors such as OPB. In this
regard, we hypothesized that TKI-resistant OXPHOS-driven oncogene-
addicted cells could have higher CSC populations. Indeed, results of
microarray gene analyses confirmed CSC enrichment in the various
models (HCC827, HCC827-GR, A375, A375-VR); heat map analysis
revealed a significant increase in CSC-associated ALDH1 in the resistant
cells (Fig. 4A). This observation was supported by higher level of
ALDH1 in HCC827-GR and A375-VR, measured using CSC-specific
markers (Supp. Fig. 5A, Fig. 4B). Notably, and in agreement with an
earlier report [21], results showed that the CSC-enriched population
(ALDH1+ sorted cells from A375VR) exhibited significantly higher OCR
compared to non-CSC population (ALDH1-), and more importantly,
OPB specifically and significantly inhibited OCR in the ALDH1+ frac-
tion (Figs. 4C and 4D). Along similar lines, CD133+ CSC fractions
isolated from A375-VR cells formed melanospheres (within seven days),
which was significantly inhibited upon incubation with OPB (Fig. 4E).
In a separate set of experiments using MCF7 breast cancer cell line
and the highly aggressive breast cancer cell line MDA-MB-231 cells as
well as two malignant derivatives of the non-transformed MCF10A
Fig. 1. Oncogene-addicted cancer cells with acquired resistance to targeted therapy exhibit elevated aerobic mitochondrial respiration and small molecule OPB
inhibits OXPHOS. (A) Basal OCR was measured using Seahorse Analyzer XFe24 in HCC827, HCC827-GR, A375, A375-VR, H2228, H2228-CR, BaF3WT and
BaF3T315I cells. (B) Mitochondrial DNA copy number was measured using qPCR and represented in terms of relative quantification (RQ) with HCC827 and A375 as
control. (C) Basal TFAM and PGC1α expression levels were measured as an indication of mitochondrial biogenesis via western blot in HCC827, HCC827-GR, H1975,
A375 and A375-VR cells with GAPDH used as a loading control. (D) Mitochondrial supercomplexes was checked via BN-PAGE using individual complex antibodies
and HSP70 was used as a loading control. (E) Selleckchem Anti-cancer compound library (414 compounds, #L3000) and Epigenetic library (151 modulators,
#L1900) were used for highthroughput chemical screening and cell viability were assayed using Celltiter-Glo luminescent. (F) HCC827, HCC827GR cells were
exposed to 1mM Metformin, 1 μM Elesclomol, 10 μM Stattic and 100 nM OPB for 4hrs before measuring OCR using Seahorse Analyzer XFe24. (G) Cell viability was
measured using crystal violet cell viability assay after 48 h exposure to 1mMMetformin, 1 μM Elesclomol, 10 μM Stattic and 100 nM OPB in HCC827and HCC827-GR
cells. (H) Cell viability was measured using crystal violet cell viability assay after 48 h of OPB treatment on HCC827, HCC827-GR, A375, A375-VR, BaF3WT and
BaFT315I cells. (I) 5 × 106 U-937 cells/body inoculated in tumor-bearing mice and allocated to 3 groups of 16 each based on body weight on the day of the
inoculation. OPB was orally administered once daily from the day after group allocation until death occurred. Figure shows the survival curve in each group
calculated by the Kaplan-Meier method. Statistical differences were determined by log-rank test using the Bonferroni correction (by two independent tests) for
multiple comparisons. P values in A, B, F, G and H were calculated by paired Student's t-test using GraphPad Prism. Therapy-resistant oncogene-addicted cell lines are
shown in red font in this and subsequent figures.
J. Hirpara et al. Redox Biology xxx (xxxx) xxxx
4
breast cancer cells (MCF10A 1aBM and MCF10A 1hBM), we verified the
association between stemness and OCR. Firstly, microarray analysis
showed a significant increase in CD44+/CD24-/EpCAM- profile in MDA-
MB231 cells compared to MCF7 (Fig. 4F). Secondly, both clones of
MCF10A and MDA-MB-231 showed equal and significant sensitivity to
OPB (Supp. Fig. 6). Notably, the CD44+/CD24--sorted fraction within
(caption on next page)
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the MDA-MB231 cells not only exhibited a significant increase in OCR
but more importantly OPB virtually completely inhibited OCR in this
fraction (Fig. 4G). In addition, a significant reduction in the CD44+/
CD24- fraction as well as inhibition of mammosphere formation were
observed upon exposure to OPB (Fig. 4H-I), further corroborating the
CSC targeting activity of the small molecule. Finally, the CD44/CD24
expression profiles (by flow cytometry) were obtained for the
MCF10A1aBM and MCF10A1hBM cells before and after OPB treatment.
Results show that exposure to OPB resulted in a significant left shift of
the populations in MCF10A1aBM (21.04% vs 1.87%) and
MCF10A1hBM (48.02% vs 0.59%), suggestive of specific targeting of
CSC-like populations (Fig. 4J). Taken together, these data provide
evidence for enrichment of CSC-like populations in oncogene-addicted
drug-resistant cancers with a preference for OXPHOS-driven bioener-
getics, and that this metabolic switch presents as a potential vulner-
ability exploited by the novel OXPHOS inhibitor, OPB.
2.6. OXPHOS inhibition re-sensitizes cancer cells with acquired resistance to
the respective targeted therapies
Having demonstrated a specific OXPHOS inhibitory activity of OPB
with potential therapeutic targeting of CSC-enriched, oncogene-ad-
dicted TKI-resistant cancers, we next set out to evaluate the efficacy of
low dose OPB in combination regimens. This is imperative based on the
observations and our current data (Fig. 2C and D) indicating that
monotherapy with relatively high doses of OXPHOS inhibitors could
have potential off target effects, in particular, increases in ECAR and
lactic acidosis. Therefore, we made use of the glycolysis inhibitor, 2-
Deoxy-D-glucose (2-DG), as a single agent and in combination with
OPB. Our results show that, while treatment of cells with 2-DG alone
did not have a significant effect, the presence of 2-DG significantly
amplified the response of cells to OPB (Supp. Fig. S7), indicating a
strong synergistic effect. Notably, 2-DG also resulted in significantly
inhibiting the increased ECAR associated with OPB treatment. To fur-
ther validate, the combination of low concentrations of OPB with ge-
fitinib and vemurafenib were assessed, particularly against cell lines
that were rendered resistant to the specific TKIs (H1975, HCC827-GR
and A375-VR). Strikingly, while all cell lines retained their selective
resistance to the specific TKI, a priori treatment for 1 h with doses of
OPB as low as 5–50 nM was sufficient to re-sensitize resistant cells to
their respective targeted-therapies, as assessed by tumor colony for-
mation (Fig. 5A), spheroid formation (Fig. 5B), and cell survival
(Fig. 5C).
2.7. OPB exerts potent anti-tumorigenic effects in vivo
Based on our findings and earlier reports, cancers with repro-
grammed reliance on OXPHOS rather than glycolysis for energy needs
will possess greater sensitivity to OXPHOS inhibitors. Therefore, as a
clinical validation of the effectiveness of OXPHOS inhibition in onco-
gene pathway driven tumors, we evaluated an extension cohort of pa-
tients with EGFR mutation positive NSCLC in a phase I study, which we
previously reported [13]. In this group of patients with secondary re-
sistance to EGFR TKIs, OPB treatment resulted in significant tumor size
reduction on compound tomography [CT] (Fig. 6A) as well as metabolic
response on 18F-Fluoro-deoxyglucose positron emission tomography
[FDG-PET] (Fig. 6B). In addition, another patient with imatinib re-
fractory c-kit mutation positive gastrointestinal stromal tumor had a
FDG-PET response to an OXPHOS inhibitor (Fig. 6C). Finally, sup-
porting the in vitro effect of OPB in NPC cells, we observed good me-
tabolic responses in a 29-year-old female with heavily pre-treated pla-
tinum-resistant NPC whose baseline FDG-PET imaging demonstrated
multiple highly FDG-avid metastatic sites. Imaging performed after 3
weeks of OPB therapy showed significant reduction in metastatic le-
sions (Fig. 6D). These data not only corroborate the in vitro findings but
also provide a clinical proof of concept highlighting the potential of
OXPHOS targeting strategies in therapy-resistant oncogene-addicted
tumors.
3. Discussion
Cancers are now thought to be flexible with regards to acquiring
fuel to drive growth and may shift from anaerobic respiration to oxi-
dative phosphorylation in response to increased energy needs.
Identification of this metabolic shift may provide a vulnerability that
can be exploited with OXPHOS inhibitors. Our current data suggests
that with the development of resistance to oncogenic pathway inhibi-
tion in oncogene-dependent cancers, OXPHOS is upregulated to drive
cellular bioenergetics, and this can be therapeutically addressed by an
OXPHOS inhibitor. This finding may not be isolated to molecular
pathway specific tumors; in certain cancers, like EBV-driven NPC,
OXPHOS may represent a viable target for drug development.
Supported by the promising metabolic responses in several patients
with relevant clinical contexts in the clinical trials, inhibition of
OXPHOS and metabolites [22] may indeed be a promising new direc-
tion for therapeutic drug development for drug-resistant cancers.
Previously, investigators have shown that in oncogene-addicted
cancers, feedback upregulation of STAT3 activation via the IL-6/JAK
and FGF/PI3K pathways represents a generalizable mechanism for re-
sistance to molecular pathway specific inhibition that could be
exploited therapeutically [9]. Further work by Genini et al. showed that
OPB binds to the SH2 domain of STAT3 with high affinity, leading to a
mitochondrial STAT3-drug interaction, which mediates mitochondrial
dysfunction through accumulation of proteotoxic aggregates that ulti-
mately leads to cell death [14]. Our work provides evidence for a novel
OXPHOS inhibitory activity of OPB, independent of STAT3, in drug-
resistant oncogene-addicted cancer cells. Furthermore, exposure to
hypoxic conditions completely abolished the growth inhibitory effect of
OPB, indicating that active OXPHOS machinery is crucial for drug-
sensitivity. Hence, we postulate that the mechanism-of-action of OPB
may be context-dependent and demonstrate here that direct mi-
tochondrial complex I inhibition is the key target in cell lines which rely
on OXPHOS for survival.
To explain the enhanced sensitivity to OXPHOS inhibition, we
Fig. 2. OPB-51602 inhibits aerobic mitochondrial respiration and induces mitochondrial dysfunction. (A) HCC827, HCC827GR, A375, A375VR and BaF3 WT/
T315I/M315T/H396R cells were exposed to 50 nM (HCC827/HCC827-GR), 20 nM (A375/A375-VR), and 10 nM (BaF3 cells) of OPB respectively for 1 h before
measuring OCR using Seahorse Analyzer XFe24. (N= 3) (B) Maximum OCR was measured using Seahorse Analyzer XFe24 with FCCP in HCC827, HCC827GR, A375
and A375VR cells after exposing to 50 nM and 20 nM of OPB respectively for 1 h. (N=3) (C) Maximum ECAR was measured using Seahorse Analyzer XFe24 in
HCC827, HCC827GR, A375, A375VR and H1975 cells after exposing to 50 nM (HCC827 and HCC827-GR) and 20 nM (A375, A375-VR and H1975) of OPB re-
spectively for 1 h. (N= 3) (D) Lactate level was measured using lactate measurement kit in H1975 cells after exposing to different doses of OPB for 1 h. (N=3) (E)
OCR measurement was done on treated (20 nM OPB) and non-treated H1975 cells using Seahorse Analyzer XFe24. Oligomycin (1 μM), FCCP (1 μM) and Rotenone/
Antimycin A (Rot/AA) (1/0.5 μM) was used in injector to check different mitochondrial complexes (F) Maximum OCR was measured using Seahorse Analyzer XFe24
with FCCP in HK-1 and C666-1 cells after exposing to 30 nM OPB for 1 h. (N=3) (G) Maximum ECAR was measured using Seahorse Analyzer XFe24 in HK-1 and
C666-1 cells after exposing to 30 nM OPB for 1 h. (N=3) (H) OCR measurement was done on treated (30 nM OPB) and non-treated HK-1 and C666-1 cells using
Seahorse Analyzer XFe24. Oligo (1 μM), FCCP (1 μM) and Rot/AA (1 μM/0.5μM) was used in injector to check different mitochondrial complexes (I) ATP level was
detected in HK and C666-1 cells after exposing to 30 nM OPB in normoxic (21%O2) and hypoxic (4%O2) condition. Error bars shown as SD, P values in A were
calculated by two ways ANOVA and C-G were calculated by paired Student's t-test.
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identified enrichment in the CSC gene expression signatures in drug-
resistant cells compared to their parental sensitive cells. This is con-
cordant with the known metabolic switch to OXPHOS to provide
augmented energy needs in CSC during cell expansion. These CSC po-
pulations were functionally reliant on OXPHOS for survival and hence
susceptible to eradication by OPB. These findings are particularly
(caption on next page)
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noteworthy because many tumors are thought to harbor CSCs, which
are notoriously resistant to standard anti-cancer therapies and are
postulated to be critical drivers of cancer relapse and metastasis
[23,24]. This phenomenon has recently been described in hemato-
poietic stem cells (HSCs), which largely remain quiescent in relatively
hypoxic tumor microenvironments and heavily rely on anaerobic gly-
colysis. However, when HSCs undergo cellular differentiation, there is a
rapid switch to an OXPHOS-upregulated state in order to meet the
metabolic needs of the cell [25]. In BCR-ABL oncogene-driven chronic
myeloid leukemia (CML), cells that were not eliminated by primary TKI
therapy were enriched in CSC and susceptible to OXPHOS inhibition
[20]. In this regard, reprogramming to OXPHOS dependence occurs as a
generalizable survival mechanism regardless of the resistance mutation
acquired in different cellular contexts, giving credence to OXPHOS as a
target of resistance cells. Given that initial response to targeted therapy
for oncogenic pathway driven malignancies is almost always temporary
and acquired resistance inevitably develops, this finding of OXPHOS
dependence is an exciting novel therapeutic strategy. Notably, recently,
evidence is emerging on the importance of OXPHOS in mediating re-
sistance to chemotherapy (docetaxel, etc) [26].
Despite prior efforts to develop OXPHOS inhibitors, there have been
challenges posed by unfavorable clinical pharmacology, lack of biolo-
gical activity and predictive biomarkers, and difficulty in achieving
tumor-selective cytotoxicity. One of the main obstacles is in the iden-
tification of highly-specific enzymatic inhibitors of bioenergetics path-
ways [27]. There are presently very few OXPHOS inhibitors with spe-
cific anti-cancer indications in clinical use or in the developmental
pipeline for tumors. Metformin possesses mitochondrial complex I in-
hibitory effects, which has led to significant efforts in repurposing it as
an anti-neoplastic agent [28,29]. However, it has yet to be determined
if the administration of metformin at clinically tolerable doses will
achieve sufficient drug levels in neoplastic tissue [30,31]. In this con-
text, our observations of clinical and imaging responses to OPB in the
appropriate malignancies that have developed resistance to specific
molecular targeted TKI treatment are highly encouraging. In theory,
OXPHOS inhibitors should drive cellular metabolism towards glyco-
lysis, which is expected to increase lesional FDG avidity on PET ima-
ging. Hence, we concluded that the FDG-PET responses observed in our
patients after several weeks of treatment are representative of genuine
anti-tumor activity of the compound, rather than a mere pharmacody-
namics effect. However, we have observed that lactic acidosis, an on-
target effect on OXPHOS, is a potentially dose-limiting adverse event,
but our further preclinical work that demonstrates synergistic effect of
OPB with the glycolytic inhibitor and relevant oncogenic pathway in-
hibitor potentially allows clinically tolerable doses to be evaluated in
combination therapy in future clinical trials.
In summary, we have characterized metabolic reprogramming as a
mechanism of acquired resistance to targeted therapies and cancer stem
cell survival, highlighting its potential as an Achilles heel in cancer
medicine. This metabolic vulnerability was successfully targeted with a
novel mitochondrial complex I inhibitor, paving the way for the clinical
development of OXPHOS inhibitors (Fig. 6E).
4. Materials and methods
4.1. Cell culture and transfection
H1975, HCC827-WT and HCC827-GR, HK1, C666-1, BaF3, H2228-
WT, H2228-CR and Jurkat cells were cultured in RPMI-1640 media
(Hyclone), while A375, A375-VR and MDA-MB-231 were cultured in
DMEM high glucose media (Hyclone); all the media were supplemented
with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin and 1%
L-glutamine. Dr. Brian Druker (Oregon Health & Science University,
USA) has generously provided BaF3 mutant P210 WT, P210 T315I,
P210 M351T, P210 H396R cells. To maintain resistance to their re-
spective drugs, cells were continuously cultured with 2 μM gefitinib
(HCC827-GR), 2 μM vemurafenib (A375-VR) and 5 μM crizotinib
(H2228-CR). All cells were kept at 37 °C with 5% CO2. For assays under
hypoxia, HK1 and C666-1 cells were subjected to 4% O2 and processed
swiftly following removal from hypoxia incubator. Transfection of
HCC827, H1975 and HK-1 was performed using Dharmafect transfec-
tion reagent (Dharmacon, USA). 24 h after transfection, cells were
washed and lysed using 1X cell lysis buffer (Cell Signaling, USA) sup-
plemented with Protease and phosphatase inhibitor cocktail
(Calbiochem, USA). The cells were lysed and cell lysates were stored at
−80 °C before analyses by western blot.
4.2. Generation of TKI-resistant Cell Lines
HCC827 cells were treated with increasing doses of gefitinib (from
1 μM to 10 μM) for 48 h to obtain the IC50 of gefitinib in the cell line.
Subsequently, the cells were cultured in T75 flasks with a starting dose
of 0.5 μM gefitinib and maintained at 2 μM gefitinib in the culture once
the cells (HCC827-GR) had developed resistance to the TKI. A375 cells
were treated with increasing doses of vemurafenib (from 0.1 μM to
2 μM) for 48 h to obtain the IC50 of vemurafenib in the cell line.
Subsequently, the cells were cultured in T75 flasks with a starting dose
of 0.1 μM vemurafenib and maintained at 2 μM vemurafenib once the
cells (A375-VR) had developed resistance to the TKI. H2228 cells were
treated with increasing doses of crizotinib (from 0.5 μM to 20 μM) for
48 h to obtain the IC50 of crizotinib in the cell line. Subsequently, the
cells were cultured in T75 flasks with a starting dose of 1 μM crizotinib
and maintained at 5 μM crizotinib in the culture once the cells (H2228-
CR) had developed resistance to the TKI.
4.3. Blue native and 2D gel electrophoresis
Mitochondrial fractions were dissolved using buffer A (200mM
Mannitol, 68mM Sucrose, 50mM Pipes-KOH pH 7.4, 50mM KCL,
5mM EGTA, 2mM Mgcl2 and 1mM DTT) and loaded onto precast
4–16% Blue native gel (Bio-Rad), which were incubated with NADH for
1 h on an orbital shaker in the presence of Nitrotetrazolium blue (NTB)
(Sigma-Aldrich, USA). Images were taken using Chemidoc software and
equipment (Bio-Rad, USA). A second gel strip was cut and loaded onto a
12% SDS-polyacrylamide gel for separation and membrane transfer as
detailed under immunoblotting.
Fig. 3. OPB-51602 specifically inhibits mitochondrial complex I activity. (A) OXPHOS regulated genes were analyzed using RT2 PCR Profiler Array in H1975 cells
after exposing the cells to 10 nM and 20 nM OPB for 48 h. (N= 3) (B) 2D gel electrophoresis was done after running BN-PAGE with mitochondrial lysates of
untreated Jurkat cells and Jurkat cells treated with 20 nM OPB. Membranes were probed with mitochondrial complex cocktail antibody (Abcam) to detect different
mitochondrial respiratory complexes. (C) Mitochondrial complex I activity was measured using Complex I activity assay kit on bovine heart mitochondria (BHM)
after exposing mitochondria with different concentrations of OPB and rotenone was used as a positive control. (N= 3) (D) Mitochondrial complex I activity was
measured in H1975 cells using complex I activity assay after treating the cells with 10 nM and 20 nM OPB for 1 h. (N= 3) (E) NAD+/NADH ratio was measured using
NAD+/NADH kit in H1975 cells treated and non-treated for 1 h with 20 nM OPB. (N=3) (F) In-gel complex I activity was measured using BN-PAGE after H1975
cells were exposed to 20 nM OPB. (G) Time kinetics OCR was measured in HK-1 and C666-1 cells with separate injection of rotenone and OPB. (H) Time kinetics OCR
was measured in HK-1 and C666-1 cells with separate injection of rotenone and different concentrations of OPB. Time interval between 2 measurements in the Y axis
is 9 min. Error bars shown as SD, P values in A, D and F were calculated by paired Student's t-test.
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4.4. OCR and ECAR measurements
Cells were plated at respective optimal densities in Seahorse XF 24-
well plates one or two days prior to the measurement. These were
subjected to the stated conditions, and incubated in Seahorse XF Assay
Media at 37 °C for 1 h without CO2 just before running the assay. Final
drug concentration was stated in Figures wheres substrate concentra-
tions were 1uM for Oligo and FCCP, 1uM/0.5uM for Rot/AA and 5mM
for succinate. All the reagents for OCR and ECAR were purchased from
Seahorse Bioscience. OCR and ECAR measurements were obtained
using the Seahorse XFe24 Analyzer, and normalized to protein con-
centration (µg/µL).
4.5. CSC population
HCC827/HCC827GR and A375/A375VR cells were stained with
ALDH using ALDHFLUOR kit (StemCell Technologies, Canada) ac-
cording to manufacturer's instruction. MDA-MB-231 and MCF10A1aBM
cells were stained with CD44 and CD24 for 30mi. in wash buffer (0.5%
BSA, 2mM EDTA in phenol free medium) at 4°C and then analyzed in
FACScalibur flow cytometer (BD LSR Fortessa). CD133, ALDH, CD44
stained cells were sorted after staining using Backman Coluter Moflow
Astrios.
4.6. Human IL-6 Enzyme-linked Immunosorbent Assay (ELISA)
Cell culture media of target cells were collected into micro-
centrifuge tubes and spun down at 1500 rpm for 10min at 4 °C to re-
move any cellular debris. The resulting supernatant was transferred to a
new tube and subjected to manufacturer's instructions of the Human IL-
6 ELISA Kit (Thermo Fisher Scientific, USA).
4.7. MtDNA quantification via qRT-PCR
Cells were collected and rinsed with PBS (1×) before lysing with
total nucleic acid lysis buffer. 1 vol of phenol (Sigma-Aldrich, USA) was
added and mixed gently on GyroMixer for 15min at room temperature,
prior to centrifugation at 14,000RPM for 5min. After centrifugation,
the aqueous top layer was transferred to a fresh eppendorf tube and
1 vol of chloroform: isoamyl alcohol 24:1 was added to the tube. The
tubes are mixed gently for 15min at room temperature, prior to cen-
trifugation at 14,000RPM for 5min. After centrifugation, the aqueous
top layer was transferred to a fresh eppendorf tube and 0.2 vol of 5M
NaCl and 0.7 vol of isopropanol were added to the tubes and incubated
on ice for 10min until DNA pellet was visible. The tubes were cen-
trifuges at 14,000RPM at 4 °C for 5min, the supernatant was removed
and DNA pellet was air dried. The DNA pellet was resuspended in
10mM Hepes-NaOH buffer (pH 7.2) and DNA concentration was
measured using Nanodrop 2000 (Thermo Fisher Scientific, USA). qPCR
was performed using SYBR™ Select Master Mix from Thermo Scientific
according to the manufacturer's instructions. Relative quantification
(RQ) was calculated from Comparative ΔΔCT method. HPRT was used
as internal normalization control.
4.8. Co-immunoprecipitation and immunoblotting
Following 4 h of 20 nM OPB treatment, H1975 cells were lysed in IP
buffer (150mM Nacl, 50mM Tris-HCL pH 7.4) supplemented with
50 µM digitonin. Protein estimation was done using Coomasie Plus
(Bradford) Protein Assay (Thermo Fisher Scientific, USA). 1mg of
protein was used to pull down GRIM19 and NDUFA9 after preclearing
using Agarose A beads. Interacting proteins were then detected by
immunoblotting as described below. Lysates were denatured in loading
buffer and resolved on 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) followed by transfer to PVDF membranes
using wet transfer method. The membrane was blocked with 5% non-fat
milk for an hour at room temperature on shaker before probing it with
appropriate primary antibodies overnight at 4 °C. The membrane were
washed thrice with TBS+0.1% Tween 20 before probing with the
isotype specific secondary IgG-HRP for an hour. After washing with TBS
+0.1% Tween 20 membranes were exposed to EZ-ECL substrate
Western Blotting Kit (Pierce, Rockford, IL, USA) and signal were de-
tected using iBright Chemidoc (Thermo Fisher Scientific, USA).
4.9. Reagents and antibodies
For STAT3 knockdown using siRNA, following targeting ON-
TARGETplus set of 4 SiRNA sequences (Dharmacon, USA) were used: 1.
GAGAUUGACCAGCAGUAUA, 2. CAACAUGUCAUUUGCUGAA, 3. CCA
ACAACCCAAGAAUGU, 4. CAACAGAUUGCCUGCAUUG
The following primers were used to check mitochondrial DNA copy
no: mtDNA, Forward primer: CCTCCTCCTAGCAGCAGC, Reverse
primer: GGTTGTGGATGATGGACCCG; HPRT, Forward primer: CCTGG
GGATTCCAAATACCT, Reverse primer: GGGCAGAAAAGGTCATCAAA.
The following antibodies were used for immunoblotting:
S727STAT3, STAT3 (Cell signaling, USA), GAPDH, β-actin, and VDAC-1
(Santa-Cruz, Dallas, TX), Y705STAT3, OXPHOS cocktail antibody,
mtTFA, PGC1α, NDUFA9, GRIM19 (Abcam, Cambridge, UK), CD44,
CD24, CD133 (BD Bioscience), FLAG, HA (Sigma-Aldrich, USA)
4.10. Crystal violet viability assay, 2D colony formation, and tumor
spheroids formation assay
Approximately 100,000 to 200,000 cells were seeded onto 12-wells
plates. 24 h after plating, cells were pre-treated with OPB for one hour.
Subsequently, gefitinib (on H1975, HCC827, HCC827-GR) or vemur-
afenib (on A375 and A375-VR) were added for total treatment duration
of 48 h. The treated cells were collected via trypsinization and re-
seeded at approximately 2000 cells/well in either 6-well plates (2D
Colony Formation Assay) or Corning® Spheroids 96-Well Microplates
(Tumor Spheroids Formation Assay). 2000 sorted CD133+ and CD44+/
CD24- cells were plated per well for spheroid formation from A375VR
and MDA-MB-231 cell line respectively. Spheroids and colonies formed
after 6 and 14 days respectively were imaged using the ZEISS® Axio
Vert. A1 Microscope.
Fig. 4. OPB inhibits cancer stemness in increased CSC population in therapy-resistant oncogene-addicted cells. (A) Microarray analysis was done in HCC827,
HCC827-GR, A375 and A375-VR cells using Agilent platform. (B) ALDH level was detected using flow cytometry in A375 basal level and in A375-VR after exposing to
20 nM OPB for 48hrs. (C) & (D) ALDH+ and ALDH- populations were sorted in A375VR cells using FACS and the sorted cells were plated and OCR was measured in
both populations after exposing the cells to 20 nM OPB for 1 h. (N= 3) (E) 2000 sorted cells of ALDH+ and ALDH- population of A375VR were plated for spheroid
formation, untreated and treated spheroids with 20 nM OPB for 7 days; Spheroids were imaged using ZEISS microscope. (F) Microarray analysis was done in MCF-7
and MDA-MB-231 cells using Agilent platform. (G) CD44+/CD24- cells were sorted using flow cytometry, sorted cells were plated and OCR was measured in CD44+/
CD24- after exposing with 100 nM OPB. (H) CD44 and CD24 levels were measured by flow cytometry in MDA-MB-231 cells after cells were exposed to 200 nM of OPB
for 48hrs. (I) 2000 sorted cells of CD44+/CD24- +ve and CD44+/CD24- -ve population of MDA-MB-231 were plated for spheroid formation, spheroids were treated
100 nM OPB for 7days and imaged using ZEISS microscope. (J) CD44 and CD24 level was measured by flow cytometry in MCF10A cells after cells were exposed to
100 nM OPB for 48hrs. Error bars shown as SD, P values in D were calculated by paired Student's t-test.
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4.11. High throughput screening
Selleckchem Anti-cancer compound Library (414 compounds,
#L3000) and Selleckchem Epigenetic Library (151 modulators,
#L1900) were used for high-throughput chemical screening. All com-
pounds were dissolved in Dimethyl sulfoxide (DMSO, Sigma Aldrich,
USA). Approximately 1500 cells were seeded per well into a 384-well
plate 24 h prior to drug treatment. For high throughput studies, cultures
(caption on next page)
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were dispensed (50 µL) into 384-well plates using a MultiFlo dispenser,
while drugs were 100-fold diluted in DMSO and kept at 1% (v/v) across
all drug concentrations and control. The viability of cells was assayed
using CellTiter-Glo luminescent (Promega, USA) after 72 h of treat-
ment. The luminescence signals were detected using TECAN Infinite
M1000 pro multi-mode plate reader using an integration time of
250ms.
4.12. Measurements of lactate concentrations, Complex I activity, and NAD
+/NADH ratio
Lactate concentrations were obtained using the Lactate Assay Kit
(Abcam, Cambridge, UK), following 20 nM OPB treatment in H1975
cells. H1975-specific Complex I activity was measured using the
Complex I assay kit (Mitoscience, USA) following 1 h treatment of 10
and 20 nM OPB. Complex-specificity of OPB was tested on bovine heart
mitochondria using a range of OPB concentrations on the MitoTox™
Complete OXPHOS Activity Assay Kit (Abcam, Cambridge, UK); a
complex-specific inhibitor was included as a positive control. The NAD
+/NADH ratio in H1975 was determined using the NAD+/NADH kit
following 1 h of 20 nM OPB treatment.
4.13. Animal work methodology
Female C.B-17/Icr-scid/scid Jcl mice were subcutaneously in-
oculated with 5 × 106 HuH-7 and SW-620,10 × 106 SNU-1, 8 × 106
HuH-28, 5 × 106 MDA-MB-231 and Caki-1, 10 × 106 H1299, 50 × 106
kG-1, 30 × 106 BALL-1, and 1 × 106 ES-2 cells/body and different
doses of OPB-51602 were administered orally once daily for 14 days
and then tumor volume was measured.
4.14. RT2 profiler PCR array
H1975 cells were treated with 10 nM and 20 nM of OPB for 48 h
prior to RNA extraction using QIAGEN RNeasy Mini Kit (QIAGEN,
Germany) according to the manufacturer's instructions. cDNA synthesis
was performed using QIAGEN RT2 First Strand cDNA synthesis kit and
qPCR measurement of customized RT2 PCR plates using Applied
Biosystem® 7500 Real-Time PCR System.
4.15. Study assessments
Safety evaluations occurred at baseline and weekly intervals for the
duration of treatment, and within 15 days of last dosing. Evaluations
included physical examination, electrocardiography, laboratory studies
(hematology, clinical chemistries and urinalysis). The serial monitoring
of serum lactate levels was introduced in cohort C, after preclinical data
demonstrated lactate accumulation in OPB-51602-treated cells. AEs
were graded according to the Common Terminology Criteria for
Adverse Events (version 4.0). Radiological assessments by computer-
ized tomography +/- radioisotope bone scans were performed during
screening and following the first cycle, and after every 2 cycles
thereafter. In the expansion cohorts, 18F-fluorodeoxyglucose-positron-
emission tomography (FDG-PET)/CT scan was used for baseline and
post-cycle 1 assessment. Lesions were evaluated using Response
Evaluation Criteria in Solid Tumors (RECIST) v1.1 and EORTC PET
response criteria.
4.16. Study approval
All studies were reviewed and approved by the IRBs of the NMRC;
the National University Hospital and written informed consent was
received from participants prior to inclusion in the study. All animals
were handled in accordance with the standards of Laboratory Animal
Care.
4.17. Statistical analysis
For all in vitro experiments, three independent experiments were
conducted and p-values were calculated using two-tailed paired or
unpaired student's t-test and two-way ANOVA using GraphPad Prism
software (Prism 7.0). P-values< 0.05 were considered statistically
significant and all P-values are mentioned in the figures and figure le-
gends.
4.18. Clinical data methodology
Clinical information was extracted from two different clinical trials
of OPB-51602 as described in earlier publication [13]. This single-arm,
open-label phase I trial was conducted in 3 cohorts; a dose-escalation,
followed by two expansion cohorts evaluating intermittent and con-
tinuous dosing of the dose lower than the maximum-tolerated-dose,
respectively. The study enrolled the patients with advanced, treatment-
refractory solid tumors; subjects were treated until disease progression
or intolerable toxicities. Radiological assessments by computerized to-
mography and radioisotope bone scans (where indicated), were per-
formed during screening and following the first cycle, and after every 2
cycles thereafter. In the expansion cohorts, 18F-fluorodeoxyglucose-
positron-emission tomography (FDG-PET)/CT scan was used for base-
line and post-cycle 1 assessment. Lesions were evaluated using Re-
sponse Evaluation Criteria in Solid Tumors (RECIST) v1.1 and EORTC
PET response criteria.
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